Cancer patients face more than just the disease. They spend countless hours commuting, waiting, and undergoing treatment.

The FDA granted breakthrough therapy status to first-line petosemtamab plus pembrolizumab for PD-L1–positive recurrent or ...

On January 15, 2025, the U.S. Department of Health and Human Services Office of Inspector General (“OIG”) posted Advisory Opinion 25-01, a ...

Galapagos shifts to CAR-T therapy with GLPG5101, targeting pivotal trials by 2026. Click here to find out why I rate GLPG ...

A Phase III trial evaluating nex-z in transthyretin amyloidosis with cardiomyopathy is underway, with plans for another ...

Among 19 neuroblastoma patients treated with CAR T-cell therapy, eight survived more than 5 years after infusion, including ...

Cancer patients spend a lot of time on their care. Meeting with doctors and other members of their health care team, getting ...

In localized non-small cell lung cancer (NSCLC), a tumor's ability to use carbon from glucose to feed the tricarboxylic acid ...

Heading into 2025, the chief item on argenx’s agenda is the FDA’s April 10 target action date to decide on the approval of a ...

Alongside a Varian TrueBeam Linear Accelerator, patients will find a boutique spa where their hair loss, lymphedema and mastectomy concerns can be addressed, and a financial counselor to help them ...

The Clemons Family Foundation has pledged $11 million to support cancer research and the completion of two building projects at UCI Health-Irvine in California.